ㅣDaily Post=Reporter Jeongeun Kimㅣ As microneedle (fine needle) technology, one of the transdermal drug delivery systems, develops, vaccines to prevent the onset and epidemic of diseases are being developed in the form of sticking to the skin.
As a result of a recent clinical trial of a patch-type measles vaccine in Gambia, West Africa, a strong immune response was confirmed, attracting attention. Measles vaccination is generally administered by injection, but research on patch-type vaccines has been conducted for the past 20 years.
Measles is a dangerous infectious disease that causes symptoms such as high fever and cough, and in the worst case, death. Vaccination can prevent the outbreak, but it has a strong contagious power that causes almost 100% of cases when a person without immunity comes into contact with a confirmed person.
Measles is known to prevent epidemics if at least 95% of the population is immunized. However, there are many areas where vaccination is slow in developing countries with weak medical infrastructure, and measles has recently re-emerged in developed countries such as the United States due to the trend of avoiding vaccination. In March 2019, a state of emergency was declared as more than 150 people suffered a group outbreak in Rockland County, New York, USA.
The patch-type measles vaccine developed by biotechnology company Micron Biomedical is a coin-sized plastic patch attached to a child’s wrist and then pressed to deliver the vaccine through a microneedle in a matter of minutes.
Since only the outer layer of the skin without pain receptors delivers the active ingredient of the vaccine through the microneedle, the child does not feel pain during vaccination.
“The patch-type measles vaccine requires no specialized skills to administer,” said Steve Damon, CEO of Micron Biomedical. do.
Micron Biomedical conducted a clinical trial in cooperation with the Gambia Medical Research Council to determine the effectiveness of the patch-type measles vaccine.
In the clinical trial, 45 adults, 120 infants aged 15 to 18 months, and 120 infants aged 9 to 10 months participated in the measles vaccine.
As a result of the research team evaluating the immune response of the test participants a month and a half after vaccination, a strong immune response was confirmed for both the injection and the patch. In a survey of parents of children participating in the clinical trial, the majority answered that they did not feel pain after vaccination with the vaccine patch, and 90% responded that the patch was superior to injection as a vaccination method.
The results of the clinical trial were announced at the Microneedle Society (Micronedles 2023) held in Seattle, USA for three days from May 15, and according to the company, the paper will soon be published in a medical journal.
“This is the first exciting result showing the potential of the MicroArry Patch (MAP) to effectively and safely deliver a vaccine,” said Dr. Ed Clarke of the Gambia Medical Research Council, who co-led the trial. Emphasized.
The patch-type vaccine can be applied not only to measles but also to other infectious diseases such as rabies, tuberculosis, and hepatitis B.
Dr. Gregory Poland, a vaccine expert at the Mayo Clinic in the U.S., said, “This technology has been a dream for a long time. There is no need to worry about body fluids and blood infection routes through the device, and no medical waste such as needles are generated.”
In addition, Birgitte Giersing, head of the World Health Organization (WHO) Vaccine Product and Delivery Research Division, said, “Measles vaccines in patch form are easy to ship to areas where medical facilities are scarce or difficult to access. It requires a dilution process. The patch type without it can be used without clean water and has the advantage of not requiring refrigeration.”
Copyright © Global News Media Channel Daily Post Unauthorized reproduction and redistribution prohibited
2023-05-31 02:37:00
#Paste #injection…patchtype #measles #vaccine #successful #results #clinical #trials
